Omkara Veeranki
Overview
Explore the profile of Omkara Veeranki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
44
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Anderson K, Braun D, Buque A, Gitto S, Guerriero J, Horton B, et al.
J Immunother Cancer
. 2023 Jul;
11(6).
PMID: 37399356
Anticancer immunotherapies, such as immune checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells, have improved outcomes for patients with a variety of malignancies. However, most patients either do...
2.
Morris J, Luthra R, Liu Y, Duose D, Lee W, Reddy N, et al.
Clin Cancer Res
. 2020 Oct;
27(1):120-130.
PMID: 33109741
Purpose: Consensus molecular subtyping (CMS) of colorectal cancer has potential to reshape the colorectal cancer landscape. We developed and validated an assay that is applicable on formalin-fixed, paraffin-embedded (FFPE) samples...
3.
Tong Z, Mejia A, Veeranki O, Verma A, Correa A, Dokey R, et al.
Ther Adv Med Oncol
. 2019 Aug;
11:1758835919864850.
PMID: 31384313
Background: CDK9 inhibitors are antitumorigenic against solid tumors, including esophageal adenocarcinoma (EAC). However, efficacy of a CDK9 inhibitor combined with 5-fluorouracil (5-FU) and target proteins that are targeted by these...
4.
Tong Z, Chatterjee D, Deng D, Veeranki O, Mejia A, Ajani J, et al.
Oncotarget
. 2017 Apr;
8(17):28696-28710.
PMID: 28404924
Role of cyclin dependent kinase 9(CDK9) as a potential target in esophageal adenocarcinoma (EAC) is unknown. We investigated CDK9 protein expression in EAC and Barrett's esophagus and role of CDK9...